Vitiligo affects roughly 0.5% to 2% of the world’s population, making it one of the more common pigmentation disorders but still relatively uncommon in everyday terms. The most rigorous pooled estimates put the figure closer to 0.36% to 0.40% globally, meaning about 1 in 250 to 1 in 280 people develop it at some point in their lives. That places vitiligo well outside the “extremely rare” category, but it’s far from something most doctors see every week.
How the Numbers Break Down
The wide range in prevalence estimates, from as low as 0.06% to as high as 2.28%, reflects real differences in how studies are conducted. Surveys that ask people directly tend to capture more cases than studies relying on medical records, because many people with small patches never seek treatment. A large population-based survey of nearly 36,000 participants across Europe, Japan, and the United States found a prevalence of 1.3%, substantially higher than the 0.2% reported in a meta-analysis that pooled data from clinic-based studies spanning 1964 to 2015.
Geography matters, too. Reported rates vary by region, though the differences likely reflect how thoroughly populations are screened rather than true biological variation. In countries with strong dermatology referral systems and lighter skin tones, vitiligo can go undiagnosed longer simply because the contrast between affected and unaffected skin is less obvious.
Who Gets Vitiligo
Vitiligo does not appear to favor one sex over the other. Studies have gone back and forth, with some finding slightly more men, others finding slightly more women, and many finding no difference at all. The most consistent conclusion is that it affects males and females at equal rates, though women may be more likely to seek medical attention for it.
The condition can start at any age, but onset follows a two-peak pattern: an early peak around age 7 and a later one around age 40. This means a significant number of cases begin in childhood or adolescence, while another wave appears in middle adulthood. Having a first-degree relative with vitiligo raises your risk noticeably. In people of European descent, about 7% of first-degree relatives of someone with vitiligo will also develop it, compared to under 1% in the general population. That familial clustering points to a genetic component, but it’s not a simple inherited trait. Dozens of genes contribute small amounts of risk, and environmental triggers play a role in whether the condition actually appears.
Segmental vs. Non-Segmental Forms
Not all vitiligo behaves the same way. The most common form, non-segmental vitiligo, causes patches that tend to appear symmetrically on both sides of the body and can spread over time. Segmental vitiligo, which stays confined to one area or one side of the body, accounts for only about 5% to 28% of all cases depending on the study. In children, the ratio is roughly 1 segmental case for every 4.6 non-segmental cases. Segmental vitiligo tends to start earlier, stabilize faster, and respond differently to treatment, so dermatologists consider it a distinct condition with its own underlying mechanisms.
Links to Other Autoimmune Conditions
Vitiligo is an autoimmune disorder, meaning the immune system mistakenly attacks the cells that produce skin pigment. That same immune tendency raises the odds of developing other autoimmune conditions. A 10-year retrospective study of 3,280 vitiligo patients found that about 23% had at least one other autoimmune disease. Thyroid disorders are the most common overlap, but the list also includes rheumatoid arthritis, inflammatory bowel disease, lupus, and type 1 diabetes. If you have vitiligo, periodic thyroid screening is a practical step that many dermatologists recommend.
Living With Vitiligo
Vitiligo doesn’t cause pain, itching, or physical disability, which is part of why it’s historically been undertreated. But its psychological impact is real. Studies measuring quality of life in vitiligo patients report average scores that are lower (meaning less impacted) than those seen in psoriasis or severe hand eczema, largely because those conditions involve physical discomfort. Still, about 1 in 4 vitiligo patients shows signs of significant mental stress, and roughly 13% report that the condition substantially interferes with daily life. The emotional burden tends to be highest in people with visible patches on the face or hands, and in cultures where skin appearance carries strong social weight.
The gap between “medically benign” and “emotionally significant” is one reason vitiligo was historically dismissed by insurers and healthcare systems. That has been shifting, particularly with the approval of newer treatments that can restore pigment in many patients. Whether vitiligo feels rare or common often depends on visibility: people with darker skin tones notice patches immediately, while those with lighter skin may not realize they have the condition until a tan reveals the contrast.